GlassScriptPhysician profile
Joseph B Quist
NPI 1053306902
$639.81
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $285 · 2021: $22.77.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $146.00 | 2019-2020 | |
| Glaxosmithkline, LLC. | $102.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.81 | 2019-2021 | |
| Global Blood Therapeutics, INC. | $67.76 | 2020 | |
| Astellas Pharma US INC | $43.81 | 2019 | |
| Lilly USA, LLC | $42.96 | 2019 | |
| Sunovion Pharmaceuticals INC. | $34.13 | 2019 | |
| Merck Sharp & Dohme LLC | $23.79 | 2020 | |
| Therapeuticsmd, INC. | $22.37 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.30 | 2020 | |
| Insmed, INC. | $21.62 | 2020 | |
| Shionogi INC | $18.33 | 2019 | |
| Allergan, INC. | $14.47 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Quist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.